Tratamiento de la hipertensión pulmonar asociada a la infección por VIH con treprostinil

Cea‐Calvo, Luis; Subías, Pilar Escribano; Menesses, Rocío Tello de; Salvador, María Lázaro; Sánchez, Miguel; Jiménez, Juan F. Delgado; Rodríguez, Celia Alonso; Caño, María José; Calzada, Carlos Sáenz de la

doi:10.1016/s0300-8932(03)76889-4

Cited by 37 publications

(6 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…All patients had improvement in NYHA FC, increased 6MW distance by at least 75 m (baseline 313–500 m), and had improvement in hemodynamics determined by echocardiography. 65 Intravenous or subcutaneous treatment requires placement of an indwelling catheter, which may not be desirable in HIV-infected patients at risk for catheter-related infection and injection drug use.…”

Section: Treatmentmentioning

confidence: 99%

Human Immunodeficiency Virus–Associated Pulmonary Arterial Hypertension

Barnett

Hsue

2013

Clinics in Chest Medicine

View full text Add to dashboard Cite

Section: Treatmentmentioning

confidence: 99%

Human Immunodeficiency Virus–Associated Pulmonary Arterial Hypertension

Barnett

Hsue

2013

Clinics in Chest Medicine

View full text Add to dashboard Cite

“…While the initial trials which established the efficacy of the parenteral prostacyclins epoprostenol and treprostinil did not include patients with HIV, these drugs seem to be well tolerated in HIV-PAH without significant drug interactions. [71][72][73][74][75] Prostacyclins can also be administered in oral and inhaled routes, and patients with HIV-PAH were included in the various clinical trials of these agents. [76][77][78] Additionally, authors of the study investigating the drug selexipag, an oral selective IP prostacyclin-receptor agonist, included patients with HIV-PAH.…”

Section: Bosentan All Pismentioning

confidence: 99%

Human Immunodeficiency Virus–Associated Pulmonary Arterial Hypertension

Kolaitis

Barnett

2022

Advances in Pulmonary Hypertension

View full text Add to dashboard Cite

Human immunodeficiency virus (HIV) attacks the immune system and can cause acquired immunodeficiency syndrome. Thankfully, antiretroviral therapy is highly effective, and people infected with HIV can live long lives with proper adherence to therapy. One of the important noninfectious complications of HIV is the development of pulmonary arterial hypertension (PAH). This review will cover the epidemiology, pathogenesis, and clinical characteristics of HIV-associated PAH. It will also cover the current knowledge on use of vasodilator therapy in this population.

show abstract

“…These drug regimens can be effectively tried for HIV-PAH as vasoactive mediators like endothelin-1 (ET-1) [159], prostacyclin (PGI 2 ) and nitric oxide (NO) are highly expressed in this condition as well. Studies evaluating specific therapy with prostanoids drugs, epoprostenol (intravenous), treprostinil (subcutaneous) [160], iloprost (inhaled) [67], and beraprost sodium (oral) [161] show potential improvement in 6MWD, hemodynamic pressures, and overall PAH symptoms in HIV-PAH patients. Although the ALPHABET study [161] showed increased 6MWD in PAH patients taking beraprost, follow-up after long-term use did not show preservation of the 6MWD improvement [162].…”

Section: Therapeutic Strategies For Hiv-pahmentioning

confidence: 99%

Drug abuse and HIV-related pulmonary hypertension

Harter

Agarwal

Dalvi

et al. 2018

Aids

View full text Add to dashboard Cite

Improved survival among HIV-1 infected individuals with the advent of antiretroviral therapy has clearly led to a greater prevalence of non-infectious complications. One of the most devastating sequelae in these individuals is the development of pulmonary arterial hypertension (PAH). Various epidemiological studies suggest a worse survival of HIV-PAH patients when compared to other forms of PAH. Given that only a subset and not all HIV-infected individuals develop HIV-PAH, suggests that an additional second hit of genetic or environmental triggers is needed for the development of PAH. In this context, it has been well documented that HIV patients who abuse illicit drugs such as stimulants, opioids etc. are more susceptible to develop PAH. In this review, we highlight the studies that support the significance of a double hit of HIV and drug abuse in the incidence of PAH and focus on the research that has been undertaken to unravel the pathobiology and vascular remodeling mechanisms underlying the deleterious synergy between HIV infection and drugs of abuse in orchestrating the development of PAH.

show abstract

Tratamiento de la hipertensión pulmonar asociada a la infección por VIH con treprostinil

Cited by 37 publications

References 10 publications

Human Immunodeficiency Virus–Associated Pulmonary Arterial Hypertension

Human Immunodeficiency Virus–Associated Pulmonary Arterial Hypertension

Human Immunodeficiency Virus–Associated Pulmonary Arterial Hypertension

Drug abuse and HIV-related pulmonary hypertension

Contact Info

Product

Resources

About